Mother and her young daughter picking colorful flower, overlayed with blue/orange gradient.
Mother and her young daughter picking colorful flower, overlayed with blue/orange gradient.
PIPELINE

Powered for
progress and
breakthrough.

A pipeline powered
for progress
Marengo’s platform drives a transformative and comprehensive portfolio supported by the ongoing efforts of a dedicated, passionate team with deep expertise in protein engineering and immuno-oncology.
Preclinical
Phase I
Tumor agnostic

(Bio-markers e.g. TMB-High, MSI-High)

STAR0602
Proof of concept & fast-to-market
Wholly owned
Tumor agnostic
Co-Star
Boost response & expand opportunities
Wholly owned
Additional solid tumors
STAR002
Extend memory

Partnered with

STAR003
Turbocharge

Partnered with

Cold tumors
Tri-STAR001
Target cold tumors
Wholly owned
SKAR001
Explore NK
Wholly owned
Asset
Description
Indication
Preclinical
Phase I
Partnerships
STAR0602
Proof of concept &
fast-to-market
Tumor
agnostic

(Bio-markers e.g. TMB-High, MSI-High)

Wholly
owned

Co-Star
Boost response & expand opportunities
Additional
solid tumors

Wholly
owned

STAR002
Extend memory
Additional
solid tumors
STAR003
Turbocharge
Additional
solid tumors
Tri-STAR001
Target cold tumors
Cold tumors

Wholly
owned

skar001
Explore NK
Cold tumors

Wholly
owned

Our first-in-class lead program, STAR0602, is a bispecific antibody fusion molecule which utilizes our STAR platform approach to bind and activate a specific Vβ T cell subset, while also delivering a costimulatory signal to the same T cell (known as cis-targeting). Using this approach, STAR0602 further “tunes” the activation and differentiation of Vβ T cells for enhanced anti-tumor activity and durability.

Marengo’s antibodies are being studied for use as monotherapies in initial development programs because of their profound single agent activity in preclinical models. We intend to explore potential combinations with a range of IO and standard-of-care treatments.

Subsequent follow on STAR programs will capitalize on validated but orthogonal T cell co-stimulators and targeting arms to expand treatments across a broad range of solid tumors.

To continue to maximize opportunities, particularly in cold tumors, Marengo is also advancing platforms that activate other types of immune cells.

3D illustration of T cells attacking cancer cells overlayed with blue background.
To continue to maximize opportunities, particularly in cold tumors, Marengo is also advancing platforms that activate other types of immune cells.